ARNA Discussion Board - Arena Neuroscience: a $1-2 billion dollar company? - ARNA Discussion Board - InvestorVillage
ARNA Discussion Board
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: ARNA Discussion Board   /  Message Board  /  Read Message


Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  49967 of 52002  at  2/27/2020 5:37:14 AM  by


Arena Neuroscience: a $1-2 billion dollar company?

Many of us have long felt that the sum of Arena's parts have never been properly valued by the market.  Hopefully this is the start of a new day for  Arena, Arena Neuroscience and who knows, eventually, Arena Cardiovascular.

It appears that Arena Neuroscience will be targeting neurodegenerative diseases like Alzheimer's, Parkinson's and Huntington's.  These are conditions that Arena could not fund or have the manpower to tackle alone.  The new company, however will have the flexibility to raise funds and eventually partner or sell itself depending upon their success.  Unfortunately, this field has been fraught with failure, so some separation from the parent Arena should provide some protection should the endeavor fail. 

I have been doing some additional research on what receptors Arena Neuroscience will likely be targeting. One of the targets will likely be S1P receptors but it is not yet clear if this will be etrasimod or a different S1P modulator.  Amit made several references to one clinical compound and two late stage preclinical compounds.  It seems possible that Arena could license etrasimod to Arena Neuroscience for certain neuroinflammatory conditions.  I will provide some of my research in a later post that supports specific receptor targets and indications.

I picked out some of the details from the conference call about the new Arena Neuroscience.  


Arena Neuroscience represents the opportunity to replicate the strategy we brought to arena 3 1/2 years ago… and now we get to do this again in neuroscience.  On the back of multiple clinical and pre-clinical compounds and an emerging platform of microglia inflammation, we are poised to progress important medicines and uncover important value for shareholders. In that context I am extremely excited that Kevin Len has agreed to lead our subsidiary Arena Neuroscience Inc. As our President and chief executive office.



Can you provide additional color on the rationale of carving out arena neuroscience now,  at this early stage and what strategic flexibility that separation gives you? Given the history of S1P in MS, is there any interest in that disease area specifically?



…It’s important that we have focus on the neuroscience area and there’s no better way to create focus then to have a senior leadership team around the compounds. Point number two is in the near term, as we progress these compounds… there will be a point in time when additional capital will be required. This allows us to bring additional capital into the neuroscience portfolio and eventually potentially split it out as a standalone company. It creates a tremendous amount of flexibility for the company overtime and I think that’s really important, but that is secondary to creating incredible focus on these compounds.


We’ve got three compounds that are either clinical or late pre-clinical stage. We have an underlying platform in microglia inflammation, it doesn’t look too dissimilar than Arena in 2016.

On the MS question we're not giving out a lot of details on the indications yet. There’s a lot of work yet to be done on these compounds I will tell you that we have shied away historically from the MS stage simply because of the competition landscape and the pending context of multiple compounds in the space.



If you look at the indications for the current S1P, the vast majority are in the neuro space. We’re excited about the potential of an S1P  (?) being focused on that as a part of neuro.


Question about Arena Neuroscience and S1P vs ceramide in neuroscience indictions:



It’s a bit early for us to discuss specific compounds and indications. We’re in the process of showing up critical pieces of animal information and intellectual property. We’ll be doing so on a future earnings call. Kevin will be building up his organization and his team. A critical piece of intellectual property needs to be filed. And some animal work needs to be completed and then we’ll come back to you and talk about that specifically.


As you’re pointing out there’s a tremendous amount of interest in GPCR projects broadly in the neuroscience space. Having both clinical and pre-clinical compounds and an underlying platform really gives us a portfolio that’s commensurate or comparable to companies in the $1 to $2 billion market cap  space that are already public. That’s a really exciting place for us.  We’re looking forward to sharing that information with you at a future point in time.   


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 36     Views: 344
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
49978 Re: Arena Neuroscience: a $1-2 billion dollar company? Rick824 0 2/27/2020 7:38:47 AM
49979 Re: Arena Neuroscience: a $1-2 billion dollar company? moegrabbedmythumb 4 2/27/2020 7:39:47 AM
49999 Re: Arena Neuroscience: a $1-2 billion dollar company=smoking something Bioimmuno 0 2/27/2020 8:39:44 AM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by